Raffinee in the treatment of spinal cord injury: An open-labeled clinical trial

Hsin Ying Chen, Jer Min Lin, Hung Yi Chuang, Wen Ta Chiu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The purpose of this preliminary clinical trial was to assess the safety and therapeutic trend of Raffinee, a mixture of free radical scavengers derived from natural products, on subacute spinal cord injury (SCI). SCI patients (three females and seven males) were enrolled from three medical centers in Taiwan. Their ages ranged from 18 to 76 years, with an average of 47.6 ± 19.0 years. There were four incomplete and six complete cases in this study. Standard regimens for SCI at acute stage were given at each hospital. Approximately 7 weeks (35.4 ± 13.9 days) after SCI, 2 U of Raffinee was given orally before meals three times a day for 6 weeks. Patients received motor, sensory, and activities of daily living (ADL) assessments before and after the treatment with Raffinee every week for 6 weeks. The Wilcoxon signed-ranks test was used for statistical analysis. Significant motor and sensory recovery began in the second week of Raffinee treatment, and significant ADL recovery was also noted in the third week. Functional recovery was more prominent in incomplete cases. Raffinee appeared to be safe in the subacute stage of SCI and may be an effective adjuvant therapy for enhancing functional recovery. Further clinical studies including double-blinded randomized placebo-controlled trials with follow-up for more than 1 year are necessary to validate the effectiveness of Raffinee in SCI.

Original languageEnglish
Pages (from-to)396-402
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume1042
DOIs
Publication statusPublished - 2005

Fingerprint

Spinal Cord Injuries
Clinical Trials
Recovery
Activities of Daily Living
Therapeutics
Free Radical Scavengers
Nonparametric Statistics
Biological Products
Taiwan
Meals
Cord
Statistical methods
Motor Activity
Randomized Controlled Trials
Placebos
Safety

Keywords

  • Free radical scavenger
  • Lipid peroxidation
  • Raffinee
  • Spinal cord injury

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Raffinee in the treatment of spinal cord injury : An open-labeled clinical trial. / Chen, Hsin Ying; Lin, Jer Min; Chuang, Hung Yi; Chiu, Wen Ta.

In: Annals of the New York Academy of Sciences, Vol. 1042, 2005, p. 396-402.

Research output: Contribution to journalArticle

Chen, Hsin Ying ; Lin, Jer Min ; Chuang, Hung Yi ; Chiu, Wen Ta. / Raffinee in the treatment of spinal cord injury : An open-labeled clinical trial. In: Annals of the New York Academy of Sciences. 2005 ; Vol. 1042. pp. 396-402.
@article{6fe9064b92ba4270b297a51e2ab33c76,
title = "Raffinee in the treatment of spinal cord injury: An open-labeled clinical trial",
abstract = "The purpose of this preliminary clinical trial was to assess the safety and therapeutic trend of Raffinee, a mixture of free radical scavengers derived from natural products, on subacute spinal cord injury (SCI). SCI patients (three females and seven males) were enrolled from three medical centers in Taiwan. Their ages ranged from 18 to 76 years, with an average of 47.6 ± 19.0 years. There were four incomplete and six complete cases in this study. Standard regimens for SCI at acute stage were given at each hospital. Approximately 7 weeks (35.4 ± 13.9 days) after SCI, 2 U of Raffinee was given orally before meals three times a day for 6 weeks. Patients received motor, sensory, and activities of daily living (ADL) assessments before and after the treatment with Raffinee every week for 6 weeks. The Wilcoxon signed-ranks test was used for statistical analysis. Significant motor and sensory recovery began in the second week of Raffinee treatment, and significant ADL recovery was also noted in the third week. Functional recovery was more prominent in incomplete cases. Raffinee appeared to be safe in the subacute stage of SCI and may be an effective adjuvant therapy for enhancing functional recovery. Further clinical studies including double-blinded randomized placebo-controlled trials with follow-up for more than 1 year are necessary to validate the effectiveness of Raffinee in SCI.",
keywords = "Free radical scavenger, Lipid peroxidation, Raffinee, Spinal cord injury",
author = "Chen, {Hsin Ying} and Lin, {Jer Min} and Chuang, {Hung Yi} and Chiu, {Wen Ta}",
year = "2005",
doi = "10.1196/annals.1338.062",
language = "English",
volume = "1042",
pages = "396--402",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Raffinee in the treatment of spinal cord injury

T2 - An open-labeled clinical trial

AU - Chen, Hsin Ying

AU - Lin, Jer Min

AU - Chuang, Hung Yi

AU - Chiu, Wen Ta

PY - 2005

Y1 - 2005

N2 - The purpose of this preliminary clinical trial was to assess the safety and therapeutic trend of Raffinee, a mixture of free radical scavengers derived from natural products, on subacute spinal cord injury (SCI). SCI patients (three females and seven males) were enrolled from three medical centers in Taiwan. Their ages ranged from 18 to 76 years, with an average of 47.6 ± 19.0 years. There were four incomplete and six complete cases in this study. Standard regimens for SCI at acute stage were given at each hospital. Approximately 7 weeks (35.4 ± 13.9 days) after SCI, 2 U of Raffinee was given orally before meals three times a day for 6 weeks. Patients received motor, sensory, and activities of daily living (ADL) assessments before and after the treatment with Raffinee every week for 6 weeks. The Wilcoxon signed-ranks test was used for statistical analysis. Significant motor and sensory recovery began in the second week of Raffinee treatment, and significant ADL recovery was also noted in the third week. Functional recovery was more prominent in incomplete cases. Raffinee appeared to be safe in the subacute stage of SCI and may be an effective adjuvant therapy for enhancing functional recovery. Further clinical studies including double-blinded randomized placebo-controlled trials with follow-up for more than 1 year are necessary to validate the effectiveness of Raffinee in SCI.

AB - The purpose of this preliminary clinical trial was to assess the safety and therapeutic trend of Raffinee, a mixture of free radical scavengers derived from natural products, on subacute spinal cord injury (SCI). SCI patients (three females and seven males) were enrolled from three medical centers in Taiwan. Their ages ranged from 18 to 76 years, with an average of 47.6 ± 19.0 years. There were four incomplete and six complete cases in this study. Standard regimens for SCI at acute stage were given at each hospital. Approximately 7 weeks (35.4 ± 13.9 days) after SCI, 2 U of Raffinee was given orally before meals three times a day for 6 weeks. Patients received motor, sensory, and activities of daily living (ADL) assessments before and after the treatment with Raffinee every week for 6 weeks. The Wilcoxon signed-ranks test was used for statistical analysis. Significant motor and sensory recovery began in the second week of Raffinee treatment, and significant ADL recovery was also noted in the third week. Functional recovery was more prominent in incomplete cases. Raffinee appeared to be safe in the subacute stage of SCI and may be an effective adjuvant therapy for enhancing functional recovery. Further clinical studies including double-blinded randomized placebo-controlled trials with follow-up for more than 1 year are necessary to validate the effectiveness of Raffinee in SCI.

KW - Free radical scavenger

KW - Lipid peroxidation

KW - Raffinee

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=22044436553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044436553&partnerID=8YFLogxK

U2 - 10.1196/annals.1338.062

DO - 10.1196/annals.1338.062

M3 - Article

C2 - 15965086

AN - SCOPUS:22044436553

VL - 1042

SP - 396

EP - 402

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -